A61K31/4535

POLYMER SYSTEM FOR OPHTHALMIC DRUG DELIVERY
20220175932 · 2022-06-09 ·

This application relates to a thermo-gel polymer system useful for ophthalmic drug delivery. The thermo-gel comprises a polymer and chitosan, and the polymer comprises monomers of N-isopropylacrylamide (NIPAAm), acrylic acid (AA) and at least one hydrophobic monomer.

Compounds and methods of promoting myelination

A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.

Compounds and methods of promoting myelination

A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.

ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB
20230270826 · 2023-08-31 ·

The present invention refers to a pharmaceutical preparation comprising liraglutide or gefitinib or a salt, solvate or combination thereof, in an effective amount for use in prophylactic or therapeutic treatment of a disease condition which is caused by or associated with an infection by a coronavirus.

ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB
20230270826 · 2023-08-31 ·

The present invention refers to a pharmaceutical preparation comprising liraglutide or gefitinib or a salt, solvate or combination thereof, in an effective amount for use in prophylactic or therapeutic treatment of a disease condition which is caused by or associated with an infection by a coronavirus.

ANTIVIRAL USE OF LIRAGLUTIDE AND GEFITINIB
20230270826 · 2023-08-31 ·

The present invention refers to a pharmaceutical preparation comprising liraglutide or gefitinib or a salt, solvate or combination thereof, in an effective amount for use in prophylactic or therapeutic treatment of a disease condition which is caused by or associated with an infection by a coronavirus.

PREVENTIVE, RELIEF OR THERAPEUTIC USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND AGAINST GASTROINTESTINAL STROMAL TUMOR

The present invention relates to the use of a 2,3,5-substituted thiophene compound for the prevention, amelioration or treatment of gastrointestinal stromal tumor. The 2,3,5-substituted thiophene compound exhibits high inhibitory activity against the growth of gastrointestinal stromal tumor, and thus may be effectively used for the prevention, amelioration or treatment of gastrointestinal stromal tumor.

PREVENTIVE, RELIEF OR THERAPEUTIC USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND AGAINST GASTROINTESTINAL STROMAL TUMOR

The present invention relates to the use of a 2,3,5-substituted thiophene compound for the prevention, amelioration or treatment of gastrointestinal stromal tumor. The 2,3,5-substituted thiophene compound exhibits high inhibitory activity against the growth of gastrointestinal stromal tumor, and thus may be effectively used for the prevention, amelioration or treatment of gastrointestinal stromal tumor.

LONG LASTING BIODEGRADABLE POLYMER BASED IN-SITU FORMING IMPLANT FOR TREATMENT OF BONE INJURIES

A pharmaceutical composition capable of forming free burst release effect in-situ forming implant useful for injection inside bone injuries without surgery is provided. This pharmaceutical composition includes; biodegradable polymer, selective estrogen receptor modulator, organic solvent and liquid lipid, solidifies upon contacting with the surrounding medium and form solid implant with compact framework by in-situ phase separation method to deliver the selective estrogen receptor modulator. This compact framework restores the porous structure of the implant by time which is essential in promoting bone healing.

LONG LASTING BIODEGRADABLE POLYMER BASED IN-SITU FORMING IMPLANT FOR TREATMENT OF BONE INJURIES

A pharmaceutical composition capable of forming free burst release effect in-situ forming implant useful for injection inside bone injuries without surgery is provided. This pharmaceutical composition includes; biodegradable polymer, selective estrogen receptor modulator, organic solvent and liquid lipid, solidifies upon contacting with the surrounding medium and form solid implant with compact framework by in-situ phase separation method to deliver the selective estrogen receptor modulator. This compact framework restores the porous structure of the implant by time which is essential in promoting bone healing.